A World without Cancer

One of the benefits of the University of Kansas Medical Center (KUMC) is access to cutting edge treatment options through clinical trials. As an academic medical center, KUMC recruits and funds research physicians whose sole function is to find better ways to prevent, diagnose, and treat cancer. As a result, patients at KUMC have access to treatment options they may not find anywhere else. For more information regarding any research study or clinical trials in general, patients, family members, friends, or referring physicians may ask their consult physician or contact Christopher Baierl, BSc, CCRP, Clinical Study Coordinator at 913-588-4721 or cbaierl@kumc.edu.

Open Clinical Trials

Department of Radiation Oncology, University of Kansas School of Medicine
Updated March 19, 2012

BRAIN

RTOG 0837 - RANDOMIZED, PHASE II, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF CONVENTIONAL CHEMORADIATION AND ADJUVANT TEMOZOLOMIDE PLUS CEDIRANIB VERSUS CONVENTIONAL CHEMORADIATION AND ADJUVANT TEMOZOLOMIDE PLUS PLACEBO IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA
Primary Objective: To determine if the addition of cediranib to chemoradiation treatment enhances treatment efficacy as measured by the 6-month progression-free survival rate.
View trial > http://www.rtog.org/ClinicalTrials/ProtocolTable/StudyDetails.aspx?study=0837

RTOG 0539 - PHASE II TRIAL OF OBSERVATION FOR LOW-RISK MENINGIOMAS AND OF RADIOTHERAPY FOR INTERMEDIATE AND HIGH-RISK MENINGIOMAS. Group I Low-risk and Group II Intermediate-risk closed to enrollment.
Primary Objective: To estimate the rates of progression-free survival (PFS) at 3 years in each of the patient risk groups.
View trial > http://www.rtog.org/ClinicalTrials/ProtocolTable/StudyDetails.aspx?study=0539

RTOG 0929 - A RANDOMIZED PHASE I/II STUDY OF ABT-888 IN COMBINATION WITH TEMOZOLOMIDE IN RECURRENT (TEMOZOLOMIDE RESISTANT) GLIOBLASTOMA
Primary Objective: To define the maximum tolerated doses of the combination of temozolomide and ABT-888 in patients with recurrent glioblastoma who have been previously treated with temozolomide.
View trial > http://www.rtog.org/ClinicalTrials/ProtocolTable/StudyDetails.aspx?study=0929

BRAIN METASTASES
M10-128 - A PHASE I STUDY EVALUATING THE SAFETY, TOLERABILITY AND PHARMACOKINETICS OF ABT-888 IN COMBINATION WITH WHOLE BRAIN RADIATION THERAPY IN SUBJECTS WITH BRAIN METASTASES

BREAST

RTOG - 1005 - A PHASE III TRIAL OF ACCELERATED WHOLE BREAST IRRADIATION WITH HYPOFRACTIONATION PLUS CONCURRENT BOOST VERSUS STANDARD WHOLE BREAST IRRADIATION PLUS SEQUENTIAL BOOST FOR EARLY-STAGE BREAST CANCER
Primary Objective: To determine whether an accelerated course of hypofractionated WBI including a concomitant boost to the tumor bed in 15 fractions following lumpectomy will prove to be non-inferior in local control to a regimen of standard WBI with a sequential boost following lumpectomy for early-stage breast cancer patients.
View trial > http://www.rtog.org/ClinicalTrials/ProtocolTable/StudyDetails.aspx?study=1005

CERVICAL

RTOG - 0724 - PHASE III RANDOMIZED STUDY OF CONCURRENT CHEMOTHERAPY AND PELVIC RADIATION THERAPY WITH OR WITHOUT ADJUVANT CHEMOTHERAPY IN HIGH-RISK PATIENTS WITH EARLY-STAGE CERVICAL CARCINOMA FOLLOWING RADICAL HYSTERECTOMY
Primary Objective: To determine if adjuvant systemic chemotherapy following chemoradiation therapy will improve disease-free survival compared to chemoradiation therapy alone in patients with high-risk earlystage cervical carcinoma found to have positive nodes and/or positive parametria after a radical hysterectomy.
View trial > http://www.rtog.org/ClinicalTrials/ProtocolTable/StudyDetails.aspx?study=0724

HEAD AND NECK

RTOG-1016 - PHASE III TRIAL OF RADIOTHERAPY PLUS CETUXIMAB VERSUS CHEMORADIOTHERAPY IN HPV-ASSOCIATED OROPHARYNX CANCER
Primary Objective: To determine whether substitution of cisplatin with cetuximab will result in comparable 5-year overall survival.
View trial > http://www.rtog.org/ClinicalTrials/ProtocolTable/StudyDetails.aspx?study=1016

RTOG-1008 - A RANDOMIZED PHASE II STUDY OF ADJUVANT CONCURRENT RADIATION AND CHEMOTHERAPY VERSUS RADIATION ALONE IN RESECTED HIGH-RISK MALIGNANT SALIVARY GLAND TUMORS
Primary Objective: Determine the feasibility of conducting a cooperative group prospective clinical trial in patients with resected malignant salivary gland tumors. Acquire preliminary efficacy data comparing postoperative radiotherapy alone to concurrent chemotherapy and radiation using weekly cisplatin.
View trial > http://www.rtog.org/ClinicalTrials/ProtocolTable/StudyDetails.aspx?study=1008

RTOG-9012 - A RANDOMIZED PHASE II STUDY OF CONCURRENT INTENSITY MODULATED RADIATION THERAPY (IMRT), PACLITAXEL AND PAZOPANIB (NSC 737754)/PLACEBO, FOR THE TREATMENT OF ANAPLASTIC THYROID CANCER
Primary Objective: To evaluate the safety of IMRT, paclitaxel, and pazopanib suspension. To evaluate and compare overall survival at 1 year from study registration.
View trial > http://www.rtog.org/ClinicalTrials/ProtocolTable/StudyDetails.aspx?study=0912

RTOG-0920 - A PHASE III STUDY OF POSTOPERATIVE RADIATION THERAPY (IMRT) +/- CETUXIMAB FOR LOCALLY-ADVANCED RESECTED HEAD AND NECK CANCER
Primary Objective: Test whether the addition of cetuximab to radiation therapy will improve overall survival (OS) in postoperative patients with intermediate risk following surgery.
View trial > http://www.rtog.org/ClinicalTrials/ProtocolTable/StudyDetails.aspx?study=0920

LUNG

RTOG-0937 - RANDOMIZED PHASE II STUDY COMPARING PROPHYLACTIC CRANIAL IRRADIATION ALONE TO PROPHYLACTIC CRANIAL IRRADIATION AND CONSOLIDATIVE EXTRA-CRANIAL IRRADIATION FOR EXTENSIVE DISEASE SMALL CELL LUNG CANCER
Primary Objective: To determine the 1-year overall median survival rate in patients with ED-SCLC with the administration of PCI alone versus PCI with consolidation extracranial RT following platinumbased chemotherapy.
View trial > http://www.rtog.org/ClinicalTrials/ProtocolTable/StudyDetails.aspx?study=0937

RTOG-1021/ACOSOG-Z4099 - A RANDOMIZED PHASE III STUDY OF SUBLOBAR RESECTION (+/- BRACHYTHERAPY) VERSUS STEREOTACTIC BODY RADIATION THERAPY IN HIGH RISK PATIENTS WITH STAGE I NON-SMALL CELL LUNG CANCER (NSCLC)
Primary Objective: To ascertain whether patients treated by SBRT have a 3-year overall survival rate that is no more than 10% less than patients treated with sublobar resection.
View trial > http://www.rtog.org/ClinicalTrials/ProtocolTable/StudyDetails.aspx?study=1021

PROSTATE

RTOG-0815 - A PHASE III PROSPECTIVE RANDOMIZED TRIAL OF DOSE-ESCALATED RADIOTHERAPY WITH OR WITHOUT SHORT-TERM ANDROGEN DEPRIVATION THERAPY FOR PATIENTS WITH INTERMEDIATE-RISK PROSTATE CANCER
Primary Objective: To demonstrate an overall survival (OS) advantage for the addition of short-term (6 months) ADT to dose-escalated RT for patients with intermediate-risk prostate cancer. The events for OS will be defined as death due to any cause.
View trial > http://www.rtog.org/ClinicalTrials/ProtocolTable/StudyDetails.aspx?study=0815

DOD - A PHASE I/II TRIAL OF POST-PROSTATECTOMY 3-D CONFORMAL RADIATION THERAPY, HORMONAL THERAPY AND CONCURRENT DOCETAXEL FOR HIGH RISK PATHOLOGIC T2-T3N0M0 PROSTATE CANCER

RTOG-0924 - ANDROGEN DEPRIVATION THERAPY AND HIGH DOSE RADIOTHERAPY WITH OR WITHOUT WHOLE-PELVIC RADIOTHERAPY IN UNFAVORABLE INTERMEDIATE OR FAVORABLE HIGH RISK PROSTATE CANCER: A PHASE III RANDOMIZED TRIAL
Primary Objective: Demonstrate that prophylactic neoadjuvant androgen deprivation therapy (NADT) and whole-pelvic radiation therapy (WPRT) will result in improvement in overall survival (OS) in patients with "unfavorable" intermediate risk or "favorable" high risk prostate cancer compared to NADT and high dose prostate and seminal vesicle (SV) radiation therapy (P + SV RT) using intensity modulated radiotherapy (IMRT) or EBRT with a high dose rate (HDR) or a permanent prostate (radioactive seed) implant (PPI) boost.
View trial > http://www.rtog.org/ClinicalTrials/ProtocolTable/StudyDetails.aspx?study=0924